Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 7/20 | 0.51 |
| ▸ | RAB9A | P51151 | 7/20 | 0.51 |
| ▸ | GRM5 | P41594 | 3/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9295949 | 0.80 | NPC1 (0.58) | L3MBTL1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL20339993 | 0.78 | TAS1R3 (0.65) | TAS1R3TAS1R1L3MBTL1NPC1RAB9A | |
| SCHEMBL28684619 | 0.78 | NPC1 (0.66) | TAS1R3L3MBTL1NPC1RAB9ACNR2 | |
| SCHEMBL9379929 | 0.77 | KMT2A (0.57) | L3MBTL1NPC1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL2920786 | 0.75 | NPC1 (0.62) | L3MBTL1NPC1RAB9ACNR2HPGD | |
| SCHEMBL2259867 | 0.75 | TSHR (0.59) | L3MBTL1SMN1; SMN2TP53KMT2A | |
| SCHEMBL24960538 | 0.75 | TAS1R3 (0.54) | TAS1R3TAS1R1L3MBTL1NPC1RAB9A | |
| SCHEMBL2930842 | 0.73 | SRD5A2 (0.48) | TAS1R3TAS1R1HPGD | |
| SCHEMBL531505 | 0.72 | TAS1R3 (0.64) | TAS1R3TAS1R1L3MBTL1NPC1RAB9A | |
| SCHEMBL5630057 | 0.72 | KMT2A (0.54) | TAS1R3L3MBTL1NPC1RAB9AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928457-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| CN-101316591-B | Quinoline compound and pharmaceutical application thereof | ARGENTA ORAL THERAPEUTICS LTD. (GB) | 2012-02-01 | — | — | CN | disclosed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | disclosed |
| CN-101316591-A | Quinolines and their therapeutic use | ARGENTA DISCOVERY LTD (GB) | 2008-12-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | NR3C1, NR3C2, NR1H3 | TAS1R3 1184/4885TAS1R1 1106/4885L3MBTL1 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.